The Influence of Exemestane on the Lipid Profile in Breast Cancer
                    Patients: A Meta-Analysis and Systematic Review of Randomized Controlled
                    Trials

Weiyuan Huang; Meiwen Zhang; Dongmei Gao

doi:10.1055/a-2543-4451

Hormone and Metabolic Research, Table of Contents

Horm Metab Res
DOI: 10.1055/a-2543-4451

Original Article: Endocrine Care

The Influence of Exemestane on the Lipid Profile in Breast Cancer Patients: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

Weiyuan Huang

¹Endocrinology Department, Zhejiang Medical and Health Group Hangzhou Hospital, Hangzhou Medical College, Hangzhou, China (Ringgold ID: RIN713496)

,

Meiwen Zhang

²Endocrinology Department, The First People’s Hospital of Hangzhou Linping District, Hangzhou, China (Ringgold ID: RIN658962)

,

Dongmei Gao

³Endocrinology Department, The First People's Hospital of Yuhang District, Hangzhou, China (Ringgold ID: RIN686828)

› Author Affiliations

Abstract

Controversial results exist regarding the influence of exemestane on serum lipids in women affected with breast cancer. Since CVD remains the predominate cause of demise in women with breast cancer and considering the long-term use of exemestane in women with breast cancer, this meta-analysis holds significant value. Hence, we carried out the current meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of exemestane treatment on lipid parameters in women with breast cancer. PubMed/Medline, Web of Science, EMBASE, and Scopus databases were explored for articles published from inception till December 3, 2024. A random effect analysis was employed for result generation as weighted mean differences (WMD) with 95% confidence intervals (CI). Six eligible and relevant RCTs were incorporated in this meta-analysis. The comprehensive findings from random effect analysis indicated a reduction in TC (WMD: –8.13 mg/dl, 95% CI: –14.48 to –1.79, p=0.012), HDL-C (WMD: –6.60 mg/dl; 95% CI: –8.17 to –5.01, p<0.001) and an increase in LDL-C (WMD: 4.66 mg/dl; 95% CI: 0.26 to 9.06, p=0.038) after exemestane intervention. Additionally, a noteworthy decline in the levels of TG was noted in studies lasting less than 12 months duration (WMD: –16.18 mg/dl; 95% CI: –25.99 to –6.37, p=0.001). Exemestane influences the lipid parameters in women with breast cancer. It elevates LDL-C levels while decreasing TC, TG, and HDL-C concentrations.

Keywords

exemestane - breast cancer women - lipid profile - high density lipoprotein - triglycerides

Full Text

References

References
1 Arnold M, Morgan E, Rumgay H. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022; 66: 15-23
2 Neal R, Tharmanathan P, France B. et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 2015; 112: S92-S107
3 Cherukuri SP, Chikatimalla R, Dasaradhan T. et al. Breast cancer and the cardiovascular disease: a narrative review. Cureus 2022; 14: e27917
4 Howe HL, Wingo PA, Thun MJ. et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93: 824-842
5 Bekes I, Huober J. Extended adjuvant endocrine therapy in early breast cancer patients – review and perspectives. Cancers 2023; 15: 4190
6 Cheung YM, Ramchand SK, Yeo B. et al. Cardiometabolic effects of endocrine treatment of estrogen receptor – positive early breast cancer. J Endocr Soc 2019; 3: 1283-1301
7 Tao W, Cai X, Al Masri MK. et al. The effect of transdermal 17b-estradiol combined with norethisterone acetate treatment on the lipid profile in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials. Steroids 2022; 185: 109061
8 Feng L, Wang L, Hernández-Wolters B. et al. The impact of medroxyprogesterone acetate on lipid profiles in Women: A time and dose-response meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023 209. 111073
9 Alomar SA, Găman MA, Prabahar K. et al. The effect of tamoxifen on the lipid profile in women: a systematic review and meta-analysis of randomized controlled trials. Exp Gerontol 2022; 159: 111680
10 Yang L, Xiang Y, Wu S. et al. The effect of exemestane administration on the lipid profile in women: meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2024; 295: 25-33
11 Bundred N. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005; 93: S23-S27
12 Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interven Aging 2008; 3: 647-657
13 Arimidex T. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643
14 Hozumi Y, Suemasu K, Takei H. et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol 2011; 22: 1777-1782
15 Atalay G, Dirix L, Biganzoli L. et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951,‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann Oncol 2004; 15: 211-217
16 Bérczi B, Farkas N, Hegyi P. et al. Aromatase inhibitors and plasma lipid changes in postmenopausal women with breast cancer: a systematic review and meta-analysis. J Clin Med 2024; 13: 1818
17 Moher D, Liberati A, Tetzlaff J. et al. Reprint – referred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 2009; 89: 873-880
18 Sterne JA, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: I4898
19 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version. 2011 Vedrsion 5.1.0
20 Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13
21 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
22 He T, Li X, Li J. et al. Lipid changes during endocrine therapy in breast cancer patients: the results of a 5-year real-world retrospective analysis. Front Oncol 2021; 11: 670897
23 Aristarco V, Serrano D, Gandini S. et al. A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients. Cancer Prev Res (Phila) 2016; 9: 349-356
24 Bell LN, Nguyen AT, Li L. et al. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol 2012; 52: 1852-1860
25 Markopoulos C, Dafni U, Misitzis J. et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009; 11: R35
26 Markopoulos C, Chrissochou M, Michailidou A. et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005; 16: 879-883
27 Lønning PE, Geisler J, Krag LE. et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137
28 Markopoulos C, Polychronis A, Zobolas V. et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005; 93: 61-66
29 Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144: S33-S42
30 Ariazi EA, Leitao A, Oprea TI. et al. Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Therap 2007; 6: 2817-2827
31 Stone T, Stachenfeld NS. Pathophysiological effects of androgens on the female vascular system. Biol Sex Differ 2020; 11: 45
32 Gibb FW, Dixon JM, Clarke C. et al. Higher insulin resistance and adiposity in postmenopausal women with breast cancer treated with aromatase inhibitors. J Clin Endocrinol Metab 2019; 104: 3670-3678
33 Thomson CA, Thompson PA, Wright-Bea J. et al. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Womens Health (Larchmt) 2009; 18: 2041-2047
34 Forbes JF, Sestak I, Howell A. et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 2016; 387: 866-873
35 Gharipour M, Sadeghi M, Nezafati P. et al. Cardiovascular disease risk assessment: triglyceride/high-density lipoprotein versus metabolic syndrome criteria. J Res Health Sci 2019; 19: e00442

Supplementary Material

Supplementary Material